Yu-Chuan Shen

Yu-Chuan Shen

Auto-generated profile, based on publicly available information

Yu-Chuan Shen

Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine Wan Fang Hospital, Taipei Medical University Taipei Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
YSYu-Chuan Shen
Yu-Chuan Shen
HHHui-Ching Hsu
Hui-Ching Hsu
TLTzu-Min Lin
Tzu-Min Lin
YCYu-Sheng Chang
Yu-Sheng Chang
LHLi-Fang Hu
Li-Fang Hu
CCChi-Ching Chang
Chi-Ching Chang
PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. This study investigated the association of AH use with the risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV-HCV virus infection. MATERIALS AND METHODS: Patients with HBV, HCV, or dual HBV-HCV infection were enrolled from Taiwan's National Health Insurance Research Database and examined for the period from January 1, 2006, to December 31, 2015. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the association between AH use and HCC risk. RESULTS: We included patients with HBV infection (n = 521,071), HCV (n = 169,159), and dual HBV-HCV (n = 39,016). Patients with HBV, HCV, or dual virus infection who used AHs exhibited significantly lower risk of HCC relative to patients who did not use AH, with their adjusted hazard ratio being 0.489 (95% CI, 0.455 to 0.524), 0.484 (95% CI, 0.450 to 0.522), and 0.469 (95% CI, 0.416 to 0.529), respectively. Furthermore, there was a dose-response relationship between AH use and the risk of HCC in the HBV cohort. The adjusted hazard ratios were 0.597 (95% CI, 0.530 to 0.674), 0.528 (0.465 to 0.600), 0.470 (0.416 to 0.531), and 0.407 (0.362 to 0.457) for AH use of 28-42, 43-63, 64-119, and ≥ 120 cumulative defined daily doses, respectively, relative to no AH use. Additionally, there was also a dose-response relationship between AH use and the risk of HCC in the HCV and dual HBV-HCV cohorts. CONCLUSION: AH use may reduce the risk for HCC among patients with HBV, HCV, or dual infection in a dose-dependent manner. Further mechanistic research is needed.

12 March 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
WCWei‐Sheng Chen
Wei‐Sheng Chen
TLTzu‐Min Lin
Tzu‐Min Lin
YCYu-Sheng Chang
Yu-Sheng Chang
YSYu‐Chuan Shen
Yu‐Chuan Shen
HHHui‐Ching Hsu
Hui‐Ching Hsu
CCChi-Ching Chang
Chi-Ching Chang
The risk of psoriasis in diabetic patients has rarely been explored. This study aims to compare the risk of incident psoriasis in patients with Type 2 diabetes (T2D) who initiate dipeptidyl peptidase‐4 inhibitors (DPP‐4is) or thiazolidinediones (TZDs) with those who initiate sulfonylureas, the most common second‐line glucose‐lowering therapy, in addition to metformin monotherapy. This sequential, propensity‐score‐matched, new‐user comparative effectiveness study utilized a target trial emulation framework. It included adults with T2D receiving metformin monotherapy, using data from 2006 to 2015 from a general population database in Taiwan. The primary outcome was the incidence of psoriasis, determined through diagnoses recorded in urgent care, hospital, and outpatient department records. Cox proportional hazards and Poisson regressions with 1:4 propensity score matching was employed to evaluate the risk factors for psoriasis after adjusting for comorbidities and the use of other medications. In 49,810 propensity score‐matched adults with T2D (27,630 men [55.4%]; mean age 57.5 years) identified in the database, the incidence rate of psoriasis in DPP‐4i users was 188 cases per 100,000 person‐years, lower than in sulfonylurea users (467 cases per 100,000 person‐years), with a hazard ratio(HR) of 0.422 (95% CI, 0.273–0.716). For the TZD vs. sulfonylurea comparison, the HR was 0.35, but the smaller matched dataset resulted in wide confidence intervals. The findings suggest that the use of DPP‐4is is associated with a lower risk of psoriasis compared to sulfonylureas in patients with T2D. These results can guide the selection of glucose‐lowering therapies in T2D patients who are at risk of developing psoriasis.

20 July 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
YCYu-Sheng Chang
Yu-Sheng Chang
YSYu-Chuan Shen
Yu-Chuan Shen
JCJin-Hua Chen
Jin-Hua Chen
CCChi-Ching Chang
Chi-Ching Chang

11 November 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
SCShih‐Chi Chen
Shih‐Chi Chen
LCLung‐Fang Chen
Lung‐Fang Chen
CWChien-Sheng Wu
Chien-Sheng Wu
YSYu‐Chuan Shen
Yu‐Chuan Shen
HHHui‐Ching Hsu
Hui‐Ching Hsu